Nav: Home

Non-alcoholic fatty liver disease shown to affect the development of coronary artery calcification

April 23, 2015

April 23, 2015, Vienna, Austria: Data revealed today at The International Liver CongressTM 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

Findings showed that the impact of NAFLD varies significantly depending on the severity of CAC at baseline. In those without CAC, NAFLD significantly affected the development of atherosclerosis; however, in patients with existing CAC at baseline NAFLD did not affect progression of the disease.

A total of 1,732 patients were included in the study:
  • Out of 1,732 patients who underwent serial CAC score evaluation, 847 patients had NAFLD and 885 patients did not have NAFLD.

  • The baseline CAC score was higher in those with NAFLD and a greater number of these patients displayed progression (48.8% vs. 38.4%, p<0.001 in subjects with vs. without NAFLD)

  • NAFLD was prospectively associated with progression of CAC score (OR 1.53, 95% CI: 1.26-1.85, p<0.001)

  • Analysis according to the severity of NAFLD showed that NAFLD in its more severe form promotes progression of CAC (adjusted OR 1.77, 95% CI: 1.08-2.88, p=0.022)

-end-
About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.

About EASL

Since EASL's foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact

For more information, please contact the ILC Press Office at:

ilc.press@easloffice.eu or
+44 (0)20 3580 5444

European Association for the Study of the Liver

Related Atherosclerosis Articles:

Running multiple marathons does not increase risk of atherosclerosis
Running multiple marathons does not increase the risk of atherosclerosis, according to research published today in the European Journal of Preventive Cardiology.
Atherosclerosis: Endogenous peptide lowers cholesterol
Cells of the innate immune system that play an important role in development of atherosclerosis contain a protein that reduces levels of cholesterol in mice -- and thus helps to inhibit or mitigate the disease.
Activation of 2 genes linked to development of atherosclerosis
Researchers at Brigham and Women's Hospital have found two new potential drug targets for treating arterial diseases such as atherosclerosis.
Promoting regulatory T cell production may help control atherosclerosis
This month in the JCI, work led by Catherine Hedrick at the La Jolla Institute for Allergy and Immunology uncovered a pathway that controls the balance between pro-inflammatory and regulatory T cells and may influence the progression of atherosclerosis.
Ring-shaped sugar helps in cases of atherosclerosis
Hardened and inflamed arteries, atherosclerosis, can be very dangerous. The consequences of atherosclerosis are among the most common causes of death in industrialized nations; in particular heart attacks and strokes.
Atherosclerosis: A short cut to inflammation
The enzyme Dicer processes RNA transcripts, cutting them into short segments that regulate the synthesis of specific proteins.
Testosterone supplementation does not result in progression of atherosclerosis
Among older men with low testosterone levels, testosterone administration for three years compared with placebo did not result in a significant difference in the rates of change in atherosclerosis (thickening and hardening of artery walls), nor was it associated with improved overall sexual function or health-related quality of life, according to a study in the Aug.
Fundamental beliefs about atherosclerosis overturned
Doctors' efforts to battle the dangerous atherosclerotic plaques that build up in our arteries and cause heart attacks and strokes are built on several false beliefs about the fundamental composition and formation of the plaques, new research from the University of Virginia School of Medicine shows.
'Cleaner' protein protects against atherosclerosis
We have an innate mechanism that ensures that our blood vessels do not become blocked.
Asymptomatic atherosclerosis linked to cognitive impairment
In a study of nearly 2,000 adults, researchers found that a buildup of plaque in the body's major arteries was associated with mild cognitive impairment.

Related Atherosclerosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...